

Arecor Therapeutics plc
("Arecor" or the "Group")

**ARECOR TO HOST COMPANY AND KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR
ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING SUPERIORITY IN PEOPLE
WITH TYPE 2 DIABETES**

- *Company will host a CEO and key opinion leader webinar at 14.30 BST*
- *AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI*
- *Confirms previous trial results in people with Type 1 diabetes, demonstrating AT278 can maintain fast and superior onset of action and glucose lowering profile irrespective of diabetes type and BMI*
- *Enables delivery of a highly concentrated, low volume injection, offering more effective mealtime glucose control to meet growing unmet need in patients requiring high daily doses of insulin*
- *Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation insulin pumps*

Cambridge, UK, 21 May 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that it will host a CEO and key opinion leader webinar on the results of its Phase I clinical trial of that its ultra-concentrated, ultra-rapid acting insulin candidate, AT278. As announced on [20 May 2024](#), AT278 met all primary and secondary endpoints, and also demonstrated superiority to NovoRapid® and Humulin® R U-500, in a Phase I clinical trial in Type 2 diabetics with a high body mass index (BMI).

AT278 (500 U/mL) is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection, even when delivered at a high concentration, and hence a lower injection volume. With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

Speakers at the webinar will be:

- **Professor Thomas Pieber, Principal Investigator for the ARE-278-104 clinical trial and Professor of Medicine, Head of the Division of Endocrinology and Metabolism and Chairman of the Department of Internal Medicine at Medical University of Graz, Austria**

- **Sarah Howell, Chief Executive Officer of Areacor**

To register to join the live webcast click [here](#) and to register for the conference line to ask questions click [here](#).

Please contact ICR Consilium for details on arecor@consilium-comms.com.

-ENDS-

For more information, please contact:

Areacor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

WG Partners LLP (Financial Advisor)

Nigel Barnes, Satheesh Nadarajah

David Wilson, Claes Spang

Tel: +44 (0)203 705 9321

ICR Consilium

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com